论文部分内容阅读
Biogen Idec公司于2011年4月宣布,其开发的口服用富马酸二甲酯(化合物代号为BG-12)可显著降低复发-缓解型多发性硬化症(RRMS)患者的2年复发率。此前,该公司开展的一项名为DEFINE、共有
Biogen Idec announced in April 2011 that its oral dimethyl fumarate (compound code BG-12) was developed to significantly reduce the 2-year relapse rate in patients with relapsing-remitting multiple sclerosis (RRMS). Previously, the company launched a project DEFINE, total